Medicenna Therapeutics Corp., a clinical stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase 2b clinical trial for the treatment of recurrent glioblastoma (rGBM), as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA55, which has completed Phase 2b clinical trial to treat rGBM; MDNA109, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease (GvHD); MDNA413, a dual IL-4/IL-13 antagonist to treat solid tumors; and MDNA132, an IL-13 Superkine to chimeric antigen receptor T (CAR-T) platform. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, or naked IL-2, IL-4, and IL-13 Superkines. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
IPO Year:
Exchange: NASDAQ
Website: medicenna.com
| Date | Price Target | Rating | Analyst |
|---|
HC Wainwright & Co. reiterated coverage of Medicenna Therapeutics with a rating of Buy and set a new price target of $7.00 from $8.00 previously
6-K - Medicenna Therapeutics Corp. (0001807983) (Filer)
6-K - Medicenna Therapeutics Corp. (0001807983) (Filer)
6-K - Medicenna Therapeutics Corp. (0001807983) (Filer)
6-K - Medicenna Therapeutics Corp. (0001807983) (Filer)
6-K - Medicenna Therapeutics Corp. (0001807983) (Filer)
6-K - Medicenna Therapeutics Corp. (0001807983) (Filer)
6-K - Medicenna Therapeutics Corp. (0001807983) (Filer)
6-K - Medicenna Therapeutics Corp. (0001807983) (Filer)
6-K - Medicenna Therapeutics Corp. (0001807983) (Filer)
25-NSE - Medicenna Therapeutics Corp. (0001807983) (Subject)
SC 13G/A - Medicenna Therapeutics Corp. (0001807983) (Subject)
SC 13G/A - Medicenna Therapeutics Corp. (0001807983) (Subject)
SC 13G/A - Medicenna Therapeutics Corp. (0001807983) (Subject)
SC 13G - Medicenna Therapeutics Corp. (0001807983) (Subject)
SC 13G/A - Medicenna Therapeutics Corp. (0001807983) (Subject)
SC 13G - Medicenna Therapeutics Corp. (0001807983) (Subject)
TORONTO and HOUSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX:MDNA, OTC:MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that a poster presentation and an oral summary highlighting long-term follow up from the Phase 2b clinical trial of bizaxofusp (formerly known as MDNA55), the Company's first-in-class IL-4R targeted therapy, will be presented at the Society for Neuro-Oncology (SNO) 2023 Annual Meeting, taking place from November 15-19, 2023, in Vancouver, Canada. The highlights of the data set will be presented by: Dr Steven Brem, M.D., Medical Director, Centre for Precisio
MDNA11 continues to demonstrate encouraging single-agent activity from the dose escalation and evaluation portion of the ABILITY-1 Study including deep ongoing partial responses with 100% reduction of target lesions in one pancreatic and 70% reduction of target lesion in one melanoma cancer patientMDNA11 also showed durable stable disease in 3 melanoma patients for at least 5 months to 18 months with concomitant shrinkage of tumor size following failure with check-point inhibitor therapiesMDNA11 is generally well tolerated with no dose-limiting toxicities or vascular leak syndrome reported in any of the dose escalation cohortsMedicenna believes that these data reaffirm the differentiated and
Company's T-MASK platform demonstrates ability to maximize anti-tumor efficacy and minimize systemic toxicity, and opportunities to explore broad range of cytokines and other potent therapeutics MDNA113 is a first-in-class IL-13R⍺2 targeted therapy that delivers a masked bi-specific IL-2-AntiPD1 Superkine to the tumor micro-environment where it is activated by cancer specific enzymes IL-13Rα2 is overexpressed by some of the most immunologically "cold" tumors with high unmet needs in pancreatic, liver, brain, breast and prostate cancer that annually affect over 2 million patients TORONTO and HOUSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Com
TORONTO and HOUSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") ((NASDAQ, TSX:MDNA), a clinical-stage immunotherapy company focused on the development of engineered cytokines, announced today that the Company received a Staff Delisting Determination from the Listing Qualifications Department of the Nasdaq Stock Market, LLC ("Nasdaq"), which notified the Company of the delisting of its securities from the Nasdaq Capital Market as a result of the Company's failure to comply with the US$1.00 per share minimum bid price requirement. The Company informed Nasdaq that it would not appeal the delisting decision or try to regain compliance by ex
New data from the Phase 1 dose-escalation and evaluation portion of the trial will be presented at the Society of Immunotherapy for Cancer (SITC) Annual Meeting on November 4, 2023 Company expects to report initial results from both the monotherapy and combination arms of the Phase 2 dose expansion study in H1 2024 TORONTO and HOUSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, today announced dosing of the first patient in the Phase 2 monotherapy dose expansion portion of the Phase 1/2 ABILITY (A Beta-only IL-2 ImmunoTherapY)
TORONTO and HOUSTON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") ((NASDAQ, TSX:MDNA), a clinical-stage immunotherapy company focused on the development of Superkines, announced poster presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer ("SITC") to be held in San Diego, CA, from November 1-5th, 2023. The company will present an update from its Phase 1/2 ABILITY Study including anti-tumor activity, safety, pharmacokinetic and pharmacodynamic data following treatment with MDNA11, a long-acting, beta-enhanced IL-2 Superkine. In addition, pre-clinical data for MDNA113, a novel first-in-class tumor-targeted and
TORONTO and HOUSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, today announced the appointment of Humphrey Gardner, M.D., as Chief Medical Officer (CMO) to lead the development strategy and execution of Medicenna's clinical programs. "We are thrilled to welcome Dr. Gardner as Medicenna's new CMO and member of our management team. Dr. Gardner holds remarkable leadership experiences advancing immune-based therapies for cancer and other diseases from the earliest stages of development through regulatory approvals," said Fahar Merc
MDNA223 is a bifunctional Superkine designed to activate cancer-killing immune cells via the IL-2 receptor while simultaneously preventing their exhaustion by blocking PD-1 signallingMDNA223 demonstrated superior efficacy and extended survival in multiple immunologically "hot" and "cold" syngeneic tumor modelsMDNA223 showed synergy with pro-inflammatory agonist (STING) to enhance tumor inhibition and induce abscopal effect TORONTO and HOUSTON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") ((NASDAQ, TSX:MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, today announced that new preclinical data chara
TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") ((NASDAQ, TSX:MDNA), a clinical-stage immuno-oncology company focused on the development of novel Superkines, today announced the voting results from the Company's annual and special meeting of shareholders held today, September 28, 2023 (the "Meeting"). Medicenna is pleased to announce that all of the nominees listed in the management information circular dated August 9, 2023 (the "Circular"), were elected as directors. Each director was elected with greater than 97% of the votes cast by shareholders present at the Meeting or represented by proxy. The results of the vote
TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") ((NASDAQ, TSX:MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, announced that the Company will present preclinical results featuring its MDNA223 BiSKIT candidate at the 2023 AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy to be held from October 1 - 4, 2023, in Toronto, Canada. Poster Title: Synergistically Engaging a β-Selective IL-2 Agonist with PD1/PDL-1 Blockade in a Bifunctional Superkine, MDNA223. Poster number: A005Poster session: October 2nd, 2023 from 4.45 PM ET – 7.00 PM ET The Company
TORONTO and HOUSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, today announced the appointment of Humphrey Gardner, M.D., as Chief Medical Officer (CMO) to lead the development strategy and execution of Medicenna's clinical programs. "We are thrilled to welcome Dr. Gardner as Medicenna's new CMO and member of our management team. Dr. Gardner holds remarkable leadership experiences advancing immune-based therapies for cancer and other diseases from the earliest stages of development through regulatory approvals," said Fahar Merc
TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") ((NASDAQ, TSX:MDNA), a clinical-stage immuno-oncology company focused on the development of novel Superkines, today announced the voting results from the Company's annual and special meeting of shareholders held today, September 28, 2023 (the "Meeting"). Medicenna is pleased to announce that all of the nominees listed in the management information circular dated August 9, 2023 (the "Circular"), were elected as directors. Each director was elected with greater than 97% of the votes cast by shareholders present at the Meeting or represented by proxy. The results of the vote
Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations Mr. Caravella's appointment demonstrates Medicenna's continuing commitment to establish its presence in Boston, the leading biotechnology ecosystem TORONTO and HOUSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company, today announced the appointment of Jeff Caravella as Chief Financial Officer (CFO). In this position, Mr. Caravella will lead Medicenna's financial strategy to support the Company's growth. This appointmen
Company to grow business development, financing and clinical leadership in Boston by accessing top-biotech talent.Brent Meadows, MBA, joins as Chief Business Officer (CBO), bringing over 25 years of large pharma and biotech experience and a track record of multiple high-value transactions in oncology and immuno-oncology.After over 6 years as CFO, Ms. Elizabeth Williams has chosen to pursue another biotech opportunity. A search for her replacement is currently underway.Company strengthens the management team with the appointment of Delphine Davan, MSc, MBA, as VP of Investor Relations, Evelyn Pau, PhD, as VP of External Collaborations; promotion of Eamonn Peters, CPA, CA to VP of Finance and
TORONTO and HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company, announced today the appointment of Dr. Arash Yavari as the Chair of its Development Advisory Committee ("DAC"), a team comprised of industry veterans in immuno-oncology drug development and regulatory strategy. "We are pleased to welcome Dr. Arash Yavari as the Chair of our Development Advisory Committee," said Dr. Fahar Merchant, President and CEO of Medicenna. "We have been working closely with Dr. Yavari on MDNA11 for the past two years and have appreciated his considerable expertise in drug development. Dr.
Medicenna's Clinical Advisory Board is comprised of thought leaders in immuno-oncology with experience in clinical development of Proleukin® and next generation IL-2 Dr. Dhingra has a track record of development and approval of cancer therapies and extensive board level expertise resulting in multiple transactions with pharma TORONTO and HOUSTON, March 03, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical stage immuno-oncology company, today announced the formation of its Clinical Advisory Board (CAB) comprised of Drs Paolo Ascierto, Lillian Siu and Hussein Tawbi and the appointment of Dr. Kapil Dhingra as a Strategic
TORONTO and HOUSTON, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical stage immuno-oncology company, today announced that Mann Muhsin has resigned as Chief Medical Officer of the Company to assume a position closer to home. Martin Bexon, MBBS, who has managed many aspects of Medicenna's clinical programs since 2016, will serve as Acting Chief Medical Officer in addition to his current role as the Medical Monitor for the Phase 1/2 ABILITY study. Medicenna also announces the appointment of industry veterans to its Development Advisory Committee. "We extend our thanks to Mann for his contributions to the Company
TORONTO and HOUSTON, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ:MDNA, TSX:MDNA), a clinical stage immuno-oncology company, today announced the appointment of John H. Sampson, MD, PhD, MBA, to its Board of Directors and the voting results from the Company's annual meeting of shareholders held today, September 23, 2021 (the "Meeting"). "John is a world-renowned clinician-scientist and I'm thrilled to welcome him to our Board," said Fahar Merchant, PhD, President and CEO of Medicenna. "We believe his extensive background in leading novel clinical trials, interactions with regulators and translational immuno-oncology expertise will b
TORONTO and HOUSTON, April 21, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical stage immuno-oncology company, today announced the appointment of Kevin Moulder, PhD, as the Company's Chief Scientific Officer (CSO). "Kevin is an ideal addition to our management team given his extensive experience leading drug discovery and development efforts in areas such as oncology and immunology," said Fahar Merchant, PhD, President and CEO of Medicenna. "We are thrilled to welcome Kevin to Medicenna as his scientific and technical expertise will be instrumental in the development of our novel Superkine and BiSKITs™ platforms and w
TORONTO and HOUSTON, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company, announced today that it will host a conference call and live webcast on August 9, 2023 at 8:30AM ET to provide a clinical update from the Phase 1/2 ABILITY study evaluating MDNA11 in patients with melanoma and other select tumors. Shareholders and financial analysts are invited to join the live audio webcast either by phone or through the webcast link. Both options to connect to the webcast are described on Medicenna's website: https://ir.medicenna.com/news-and-events/events-and-presentations The webcast will b
Safety Review Committee clears MDNA11 Cohort 6 dose of 120µg/Kg, Q2W, in the Phase 1 portion of the ABILITY Study as there were no protocol defined dose-limiting toxicitiesMDNA11 clinical update scheduled for August 9; conference call to discuss data from cohorts five and six, recommended dose for monotherapy expansion and details on Phase 2 trial design$29.6 million in cash and cash equivalents as of June 30, 2023 provides expected runway through the completion of the ABILITY study and through calendar Q3 2024 TORONTO and HOUSTON, July 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy compa
Phase 1/2 ABILITY study advancing to sixth dose escalation cohort following positive review of safety and pharmacodynamic data from fifth cohort Initial PK/PD data from ABILITY's fifth dose escalation cohort expected alongside updated anti-tumor data in calendar Q1 2023$36.2 million in cash and cash equivalents at December 31, 2022 provides expected runway through the completion of the ABILITY study and through calendar Q2 2024 Management hosting conference call and webcast today at 8:30 am ET TORONTO and HOUSTON, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical stage immunotherapy company, today announced it
TORONTO and HOUSTON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on February 7, 2023 at 8:30 AM ET to report its third quarter fiscal 2023 financial results and operational highlights. To access the call, please dial 1-877-407-9716 from Canada or the United States or 1-201-493-6779 internationally, followed by the conference ID: 13735304. To access the live webcast, please visit https://viavid.webcasts.com/starthere.jsp?ei=1592653&tp_key=4301c2d5bb. Following the live webcast, an archived version of the ca
TORONTO and HOUSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on November 4, 2022 at 8:30 AM ET to report its second quarter fiscal 2023 financial results and operational highlights. To access the call, please dial 1-877-407-9716 from Canada or the United States or 1-201-493-6779 internationally, followed by the conference ID: 13733195. To access the live webcast, please visit https://viavid.webcasts.com/starthere.jsp?ei=1573316&tp_key=64173fbac0. Following the live webcast, an archived version of the c
TORONTO and HOUSTON, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on August 15, 2022 at 8:30 AM ET to report its first quarter fiscal 2023 financial results and operational highlights. To access the call, please dial 1-877-407-9716 from Canada or the United States or 1-201-493-6779 internationally, followed by the conference ID: 13731985. To access the live webcast, please go visit https://viavid.webcasts.com/starthere.jsp?ei=1560574&tp_key=dc821e35e8. Following the live webcast, an archived version of the
--Cash runway extended late into calendar Q2 2023 --Tumor control achieved following MDNA11 treatment in 3 out of 8 patients enrolled in first 3 dose escalation cohorts of the ABILITY Phase 1/2 Study. -- Pharmacodynamic data show superior dose-dependent increase in stimulation of anti-cancer immune cells when compared to competing IL-2 programs in the clinic -- Management hosting conference call and webcast today at 8:30 AM ET TORONTO and HOUSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical stage immunotherapy company, today announced its financial results and operational highlights for the fi
TORONTO and HOUSTON, June 07, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on June 22, 2022 at 8:30 AM ET to report its fiscal year 2022 financial results and operational highlights. To access the call, please dial 1-877-407-9716 from Canada or the United States or 1-201-493-6779 internationally, followed by the conference ID: 13729367. To access the live webcast, please go visit https://viavid.webcasts.com/starthere.jsp?ei=1544577&tp_key=400e62120f. Following the live webcast, an archived version of the call will b
-- Phase 1/2 ABILITY study of MDNA11 on track with first set of efficacy results from early dose escalation cohorts expected in mid-calendar 2022 -- Preliminary pharmacodynamic data show preferential stimulation of anti-cancer immune cells with MDNA11 treatment in the ABILITY study -- First clinical site in the US open for enrolment -- Management hosting conference call and webcast today at 8:30 am ET TORONTO and HOUSTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical stage immuno-oncology company, today announced its financial results and operational highlights for the quarter ended December 31, 2021. A
TORONTO and HOUSTON, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on February 9, 2022 at 8:30 AM ET to report its third quarter fiscal 2022 financial results and operational highlights. To access the call, please dial (877) 407-9716 from the Canada and the United States or (201) 493-6779 internationally, followed by the conference ID: 13726690. To access the live webcast, please go visit https://viavid.webcasts.com/starthere.jsp?ei=1526480&tp_key=191321ca33. Following the live webcast, an archived version o
Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX:MDNA, OTC:MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that a poster presentation and an oral summary highlighting long-term follow up from the Phase 2b clinical trial of bizaxofusp (formerly known as MDNA55), the Company's first-in-class IL-4R targeted therapy, will be presented at the Society for Neuro-Oncology (SNO) 2023 Annual Meeting, taking place from November 15-19, 2023, in Vancouver, Canada. The highlights of the data set will be presented by:Dr Steven Brem, M.D., Medical Director, Centre for Precision Surgery, Abramson Cancer Center, Perelman School of Medici
Company's T-MASK platform demonstrates ability to maximize anti-tumor efficacy and minimize systemic toxicity, and opportunities to explore broad range of cytokines and other potent therapeutics MDNA113 is a first-in-class IL-13R⍺2 targeted therapy that delivers a masked bi-specific IL-2-AntiPD1 Superkine to the tumor micro-environment where it is activated by cancer specific enzymesIL-13Rα2 is overexpressed by some of the most immunologically "cold" tumors with high unmet needs in pancreatic, liver, brain, breast and prostate cancer that annually affect over 2 million patientsTORONTO and HOUSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (
Gainers Miromatrix Medical Inc. (NASDAQ:MIRO) shares jumped 232% to $3.36 in pre-market trading. United Therapeutics Corporation (NASDAQ:UTHR) agreed to acquire Miromatrix Medical for $3.25 per share in cash (an aggregate of approximately $91 million). Conduit Pharmaceuticals Inc. (NASDAQ:CDT) shares surged 70.6% to $1.74 in pre-market trading after falling more than 12% on Friday. reAlpha Tech Corp. (NASDAQ:AIRE) shares gained 22% to $28.26 in pre-market trading after dipping around 54% on Friday. My Size, Inc. (NASDAQ:MYSZ) shares climbed 21.4% to $0.8498 in pre-market trading. Coherus BioSciences, Inc. (NASDAQ:CHRS) shares rose 16.2% to $3.07 in pre-market trading. Coherus and Junsh
Gainers Apollomics, Inc. (NASDAQ:APLM) shares surged 88.4% to $1.07 stoma multiforme with PTPRZ-MET fusion. BIO-key International, Inc. (NASDAQ:BKYI) jumped 53.5% to $0.2620 after the company said ALPI Portugal Lda. has deployed AuthControl Sentry company-wide for enhanced data access security through BIO-key. SeaStar Medical Holding Corporation (NASDAQ:ICU) shares climbed 42.5% to $1.1284. SeaStar Medical Holding said it is requesting to withdraw the registration statement because it has elected not to pursue the sale of securities pursuant to the registrant statement at this time due to prevailing market conditions. NerdWallet, Inc. (NASDAQ:NRDS) gained 27.7% to $8.48 following str
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining more than 100 points on Friday. Following the market opening Friday, the Dow traded down 0.12% to 32,744.42 while the NASDAQ rose 0.82% to 12,699.50. The S&P 500 also rose, gaining, 0.24% to 4,147.09. Check This Out: Amazon To Rally Around 55%? Here Are 10 Top Analyst Forecasts For Friday Leading and Lagging Sectors Consumer discretionary shares rose by 2.4% on Friday. In trading on Friday, energy shares dipped by 1.7%. Top Headline Amazon.com Inc (NASDAQ:AMZN) reported stronger-than-expected results for its third quarter on Thursday. Amazon said revenue increased 13% year-over-year to $143.
New data from the Phase 1 dose-escalation and evaluation portion of the trial will be presented at the Society of Immunotherapy for Cancer (SITC) Annual Meeting on November 4, 2023 Company expects to report initial results from both the monotherapy and combination arms of the Phase 2 dose expansion study in H1 2024TORONTO and HOUSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, today announced dosing of the first patient in the Phase 2 monotherapy dose expansion portion of the Phase 1/2 ABILITY (A Beta-only IL-2 ImmunoTherapY) study
Friday's session saw 112 companies set new 52-week lows. Intriguing Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Hershey (NYSE:HSY). The smallest company on a market cap basis to set a new 52-week low was Ascent Solar Technologies (NASDAQ:ASTI). TOP Ships (NASDAQ:TOPS)'s stock fell the most, as it traded down 1028.56% to reach a new 52-week low. Quest Diagnostics (NYSE:DGX) shares were the most resilient, as shares rose 0.0%, rebounding from its new 52-week low. Stocks dropping to new 52-week lows on Friday: Quest Diagnostics (NYSE:DGX) stock hit a yearly low of $122.00. The stock was 0.0% (flat) for the day. JM Smucker (NYS